CIDP
MCID: CHR283
MIFTS: 52

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Categories: Immune diseases, Muscle diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Chronic Inflammatory Demyelinating Polyneuropathy

MalaCards integrated aliases for Chronic Inflammatory Demyelinating Polyneuropathy:

Name: Chronic Inflammatory Demyelinating Polyneuropathy 39 77 54 55 60 17
Chronic Inflammatory Demyelinating Polyradiculoneuropathy 54 60
Cidp 54 60
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating 74

Characteristics:

Orphanet epidemiological data:

60
chronic inflammatory demyelinating polyneuropathy
Inheritance: Not applicable; Age of onset: Adolescent,Adult,Childhood,Elderly; Age of death: normal life expectancy;

Classifications:

Orphanet: 60  
Rare neurological diseases


External Ids:

ICD10 via Orphanet 35 G61.8
UMLS via Orphanet 75 C0393819
Orphanet 60 ORPHA2932
UMLS 74 C0393819

Summaries for Chronic Inflammatory Demyelinating Polyneuropathy

NIH Rare Diseases : 54 Chronic inflammatory demyelinating polyneuropathy (CIDP) is a neurological disorder that causes progressive weakness and impaired sensory function in the legs and arms. Symptoms often include tingling or numbness (first in the toes and fingers), weakness of the arms and legs, loss of deep tendon reflexes, fatigue, and abnormal sensations. Other symptoms may include pain, difficulty swallowing (dysphagia), and double vision (diplopia). CIDP is thought to be caused by the immune system mistakenly attacking and damaging the myelin sheath (protective cover of nerve fibers) of the peripheral nerves. CIDP is closely related to Guillain-Barre syndrome (GBS) and is considered the "chronic counterpart" of GBS. Treatment may include corticosteroids, immunosuppressant drugs, plasma exchange, physical therapy, and/or intravenous immunoglobulin (IVIG) therapy. Left untreated, 30% of people with CIDP will progress to wheelchair dependence.

MalaCards based summary : Chronic Inflammatory Demyelinating Polyneuropathy, also known as chronic inflammatory demyelinating polyradiculoneuropathy, is related to multifocal motor neuropathy and demyelinating polyneuropathy. An important gene associated with Chronic Inflammatory Demyelinating Polyneuropathy is HP (Haptoglobin), and among its related pathways/superpathways are Cell adhesion molecules (CAMs) and L1CAM interactions. The drugs Immunoglobulins and Rho(D) Immune Globulin have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone and skin, and related phenotypes are paresthesia and areflexia

NINDS : 55 Chronic inflammatory demyelinating polyneuropathy (CIDP) is a neurological disorder characterized by progressive weakness and impaired sensory function in the legs and arms. The disorder, which is sometimes called chronic relapsing polyneuropathy, is caused by damage to the myelin sheath (the fatty covering that wraps around and protects nerve fibers) of the peripheral nerves. Although it can occur at any age and in both genders, CIDP is more common in young adults, and in men more so than women. It often presents with symptoms that include tingling or numbness (beginning in the toes and fingers), weakness of the arms and legs, loss of deep tendon reflexes (areflexia), fatigue, and abnormal sensations. CIDP is closely related to Guillain-Barre syndrome and it is considered the chronic counterpart of that acute disease.

Wikipedia : 77 Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired immune-mediated inflammatory... more...

Related Diseases for Chronic Inflammatory Demyelinating Polyneuropathy

Diseases in the Demyelinating Polyneuropathy family:

Chronic Inflammatory Demyelinating Polyneuropathy Subacute Inflammatory Demyelinating Polyneuropathy

Diseases related to Chronic Inflammatory Demyelinating Polyneuropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 170)
# Related Disease Score Top Affiliating Genes
1 multifocal motor neuropathy 30.4 CNTN2 FCGR2B
2 demyelinating polyneuropathy 30.0 AIF1 CNTN2 FCGR2B HP NFASC TTR
3 peripheral nervous system disease 29.3 NFASC TTR
4 chronic inflammatory demyelinating polyradiculoneuropathy 12.8
5 lewis-sumner syndrome 11.7
6 chronic inflammatory demyelinating polyneuritis 11.5
7 polyneuropathy 11.4
8 x-linked charcot-marie-tooth disease 11.4
9 polyradiculoneuropathy 11.4
10 guillain-barre syndrome, familial 11.1
11 neuropathy 10.7
12 hepatitis 10.5
13 diabetes mellitus 10.4
14 myasthenia gravis 10.4
15 charcot-marie-tooth disease 10.4
16 tooth disease 10.4
17 myasthenia gravis congenital 10.4
18 multiple sclerosis 10.4
19 lymphoma 10.4
20 poems syndrome 10.4
21 melanoma 10.4
22 lupus erythematosus 10.4
23 hepatitis b 10.3
24 systemic lupus erythematosus 10.2
25 membranous nephropathy 10.2
26 glomerulonephritis 10.2
27 respiratory failure 10.2
28 guillain-barre syndrome 10.2
29 hepatitis c 10.2
30 psoriasis 10.2
31 tremor 10.2
32 carpal tunnel syndrome 10.2
33 charcot-marie-tooth disease, demyelinating, type 1a 10.2
34 focal segmental glomerulosclerosis 1 10.2
35 hepatitis c virus 10.2
36 mononeuropathy of the median nerve, mild 10.2
37 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 10.2
38 arthritis 10.2
39 crohn's disease 10.2
40 diabetic neuropathy 10.2
41 focal segmental glomerulosclerosis 10.2
42 leukemia 10.2
43 scoliosis 10.2
44 abducens nerve disease 10.2
45 diabetic polyneuropathy 10.2
46 mononeuritis multiplex 10.2
47 sensory peripheral neuropathy 10.2
48 myopathy 10.2
49 intracranial hypertension 10.2
50 amyloid neuropathy 10.2

Graphical network of the top 20 diseases related to Chronic Inflammatory Demyelinating Polyneuropathy:



Diseases related to Chronic Inflammatory Demyelinating Polyneuropathy

Symptoms & Phenotypes for Chronic Inflammatory Demyelinating Polyneuropathy

Human phenotypes related to Chronic Inflammatory Demyelinating Polyneuropathy:

60 33 (show all 17)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 paresthesia 60 33 hallmark (90%) Very frequent (99-80%) HP:0003401
2 areflexia 60 33 hallmark (90%) Very frequent (99-80%) HP:0001284
3 fatiguable weakness of proximal limb muscles 60 33 hallmark (90%) Very frequent (99-80%) HP:0030200
4 unsteady gait 60 33 hallmark (90%) Very frequent (99-80%) HP:0002317
5 segmental peripheral demyelination/remyelination 60 33 hallmark (90%) Very frequent (99-80%) HP:0003481
6 sensory ataxia 60 33 hallmark (90%) Very frequent (99-80%) HP:0010871
7 motor conduction block 60 33 hallmark (90%) Very frequent (99-80%) HP:0012078
8 falls 60 33 frequent (33%) Frequent (79-30%) HP:0002527
9 difficulty walking 60 33 frequent (33%) Frequent (79-30%) HP:0002355
10 difficulty climbing stairs 60 33 frequent (33%) Frequent (79-30%) HP:0003551
11 hand muscle weakness 60 33 frequent (33%) Frequent (79-30%) HP:0030237
12 spontaneous pain sensation 60 33 occasional (7.5%) Occasional (29-5%) HP:0010833
13 peripheral neuropathy 60 Very frequent (99-80%)
14 decreased nerve conduction velocity 60 Very frequent (99-80%)
15 peripheral demyelination 60 Very frequent (99-80%)
16 sensory impairment 60 Very frequent (99-80%)
17 abnormal nerve conduction velocity 60 Very frequent (99-80%)

Drugs & Therapeutics for Chronic Inflammatory Demyelinating Polyneuropathy

Drugs for Chronic Inflammatory Demyelinating Polyneuropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 67)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
2 Rho(D) Immune Globulin Phase 4,Phase 3,Phase 2,Not Applicable
3 gamma-Globulins Phase 4,Phase 3,Phase 2,Not Applicable
4 Immunoglobulins, Intravenous Phase 4,Phase 3,Phase 2,Not Applicable
5 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
6 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Immunoglobulin G Phase 4,Phase 3,Phase 2,Not Applicable
8 Antineoplastic Agents, Immunological Phase 4,Phase 2,Phase 1
9
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
10
tannic acid Approved Phase 3 1401-55-4
11
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
12
Glycine Approved, Nutraceutical, Vet_approved Phase 3 56-40-6 750
13 Fingolimod Hydrochloride Phase 3
14 Immunosuppressive Agents Phase 3,Phase 1,Phase 2
15 Hormone Antagonists Phase 3,Phase 1,Phase 2
16 Antineoplastic Agents, Hormonal Phase 3,Phase 1,Phase 2
17 glucocorticoids Phase 3,Phase 1,Phase 2
18 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 1,Phase 2
19 Anti-Inflammatory Agents Phase 3,Phase 1,Phase 2
20 Hormones Phase 3,Phase 1,Phase 2
21 Pharmaceutical Solutions Phase 3,Phase 2
22
Interferon beta-1a Approved, Investigational Phase 2 145258-61-3 6438354
23
rituximab Approved Phase 2,Phase 1 174722-31-7 10201696
24
Cyclophosphamide Approved, Investigational Phase 1, Phase 2,Phase 2 6055-19-2, 50-18-0 2907
25
Lenograstim Approved, Investigational Phase 1, Phase 2 135968-09-1
26
Methylprednisolone Approved, Vet_approved Phase 1, Phase 2 83-43-2 6741
27
Methylprednisolone hemisuccinate Approved Phase 1, Phase 2 2921-57-5
28
Prednisolone Approved, Vet_approved Phase 1, Phase 2 50-24-8 5755
29
Mesna Approved, Investigational Phase 1, Phase 2 3375-50-6 598
30
Prednisolone phosphate Approved, Vet_approved Phase 1, Phase 2 302-25-0
31
Sargramostim Approved, Investigational Phase 1, Phase 2 123774-72-1, 83869-56-1
32
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
33
Prednisolone hemisuccinate Experimental Phase 1, Phase 2 2920-86-7
34 Protective Agents Phase 2,Phase 1
35 Thioctic Acid Phase 2
36 Micronutrients Phase 2
37 Vitamin B9 Phase 2
38 Folate Phase 2
39 Antioxidants Phase 2
40 Alpha-lipoic Acid Phase 2
41 Vitamins Phase 2
42 Trace Elements Phase 2
43 Nutrients Phase 2
44 Vitamin B Complex Phase 2
45 Anti-Infective Agents Phase 2
46 Adjuvants, Immunologic Phase 2,Phase 1
47 Antiviral Agents Phase 2
48 Interferon-beta Phase 2
49 interferons Phase 2
50 Antirheumatic Agents Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 52)
# Name Status NCT ID Phase Drugs
1 IVIg for Demyelination in Diabetes Mellitus Unknown status NCT02372149 Phase 4 10% intravenous immunoglobulin (IVIg);0.9% sodium chloride
2 MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study Completed NCT03226119 Phase 4
3 Single vs. Multiple Privigen Dose Regimens in Pediatric CIDP Not yet recruiting NCT03684018 Phase 4
4 Alemtuzumab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIPD) Withdrawn NCT01757574 Phase 4 Alemtuzumab infusion
5 Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Chronic Inflammatory Demyelinating Polyneuropathy. Completed NCT01824251 Phase 3 NPB-01
6 Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT01184846 Phase 3
7 Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients. Completed NCT01625182 Phase 3 Fingolimod;Placebo Comparator
8 Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT02027701 Phase 3
9 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20) Completed NCT01545076 Phase 3
10 Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT00220740 Phase 3 Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified;Albumin (Human) 25%, United States Pharmacopeia (USP)
11 Randomized Open-label Trial to Compare Efficacy and Tolerance of Corticosteroids and IVIg Completed NCT01349270 Phase 3 Immunoglobulin perfusion;Prednisone
12 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT00004772 Phase 3 Immune globulin
13 Efficacy and Safety Study of I10E in Treatment of Patients With CIDP Completed NCT02293460 Phase 3 I10E
14 Phase III Multicenter Double Blind Controlled Trial of Human Immune Globulin Therapy in Previously Untreated Patients With Chronic Inflammatory Demyelinating Neuropathy Completed NCT00004286 Phase 3 immune globulin
15 Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP Recruiting NCT02955355 Phase 3
16 Phase III Efficacy, Safety, and Tolerability Study of HYQVIA/HyQvia and GAMMAGARD LIQUID/KIOVIG in CIDP Recruiting NCT02549170 Phase 3
17 Study to Evaluate Safety and Efficacy of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly (Radiculo) Neuropathy Recruiting NCT02638207 Phase 3 NewGam
18 Panzyga in CIDP Administered at Different Infusion Rates Not yet recruiting NCT03166527 Phase 3 Immune Globulin 10% Intravenous Solution
19 Efficacy and Safety Study of I10E in the Maintenance Treatment of Patients With CIDP: Extension of PRISM Study I10E-1302 Terminated NCT02317562 Phase 3 I10E
20 Safety and Efficacy Study of Three Different Dosages of NewGam in Patients With CIDP Terminated NCT01225276 Phase 2, Phase 3 NewGam 10%;Placebo;NewGam 10%;NewGam 10%
21 SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study Unknown status NCT02967679 Phase 1, Phase 2 MD1003
22 Lipoic Acid to Treat Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT00962429 Phase 2 lipoic acid
23 Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Completed NCT00099489 Phase 2 Interferon Beta-1a
24 Intravenous Immunoglobulin (IVIg) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT00001287 Phase 2 intravenous immunoglobulin (IVIg)
25 Subcutaneous Immunoglobulin Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Completed NCT01017159 Phase 2 Subcutaneous immunoglobulin
26 The Evaluation of Efficacy and Safety of Rituximab in Refractory CIDP Patients With IgG4 Autoantibodies Recruiting NCT03864185 Phase 2
27 Hematopoietic Stem Cell Transplantation in Chronic Inflammatory Demyelinating Polyneuropathy Active, not recruiting NCT00278629 Phase 2
28 Stem Cell Transplantation for Stiff Person Syndrome (SPS) Active, not recruiting NCT02282514 Phase 1, Phase 2 Cyclophosphamide;Mesna;rATG;Methylprednisolone;G-CSF;Rituxan
29 A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy Not yet recruiting NCT03861481 Phase 2 Rozanolixizumab
30 High-dose Cyclophosphamide for Moderate to Severe Refractory Chronic Inflammatory Demyelinating Polyneuropathy Withdrawn NCT01236456 Phase 2 Cyclophosphamide
31 Pilot Study of Acthar® Gel in Chronic Inflammatory Demyelinating Neuropathy Withdrawn NCT02574962 Phase 2 H.P. Acthar® Gel
32 Prevalence of Decreased Corneal Sensation in Patients With Chronic Inflammatory Demyelinating Polyneuropathy Unknown status NCT01379833
33 sCD163 & CD19 as Candidate Biomarkers in CIDP and MMN Unknown status NCT02271724
34 Diffusion Tensor Imaging in Chronic Inflammatory Demyelinating Polyneuropathy (PIDC) Completed NCT03460951
35 Effect of Resistance and Aerobic Exercise in CIDP or MMN Completed NCT02121678 Not Applicable
36 MRI in Diagnosing and Monitoring CIDP Completed NCT02017769
37 Study of CIDP Patients During IVIG Treatment Completed NCT00305266 intravenous gammaglobulin
38 Immunoglobulin Dosage and Administration Form in CIDP and MMN Completed NCT02111590 Immunoglobulins
39 Study Assessing Risk of Autoimmune Diseases in Females (9 - 25 Years) Exposed to Cervarix® in United Kingdom Completed NCT01953822
40 Magnetic Resonance Diagnostics of Diabetic Peripheral Neuropathy Completed NCT01847937
41 Postmarketing Safety Surveillance European Registry of Crohn's Disease Patients Treated With Remicade or Standard Therapy (MK-2155-035) Completed NCT00705614
42 Evaluating the Effectiveness of Telemonitoring System in the Management of Patients With CIDP Recruiting NCT03779828
43 Biomark Study: Predict Intravenous Immunoglobulin Responders in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Recruiting NCT02629796
44 Early Diagnosis of TTR Amyloidosis by Use of Molecular Biology Recruiting NCT03373370
45 Clinical Trial to Assess the Safety of a Novel Scaffold Biomaterial Recruiting NCT03584022 Not Applicable
46 Trial Assessing Safety and Efficacy of Gammanorm® in Autoimmune Diseases Recruiting NCT03656640 Gammanorm
47 IVIg Treatment-Related Fluctuations in CIDP Patients Using Daily Grip Strength Measurements Active, not recruiting NCT02414490 Intravenous Immunoglobulin
48 Subcutaneous Immunoglobulin for CIDP Active, not recruiting NCT02465359 Not Applicable Immune Globulin Subcutaneous (Human)
49 Transcriptome Analysis of the Peripheral Blood in CIDP Active, not recruiting NCT02404298 Not Applicable IVIg
50 Non-invasive Vagus Nerve Stimulation (nVNS) in Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Not yet recruiting NCT03772717 Not Applicable Standard of Care

Search NIH Clinical Center for Chronic Inflammatory Demyelinating Polyneuropathy

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Stem-cell-based therapeutic approaches for Chronic Inflammatory Demyelinating Polyneuropathy:
Hematopoietic stem cells for treatment of chronic inflammatory demyelinating polyneuropathy
Embryonic/Adult Cultured Cells Related to Chronic Inflammatory Demyelinating Polyneuropathy:
Bone marrow-derived hematopoietic stem cells PMIDs: 17277794

Genetic Tests for Chronic Inflammatory Demyelinating Polyneuropathy

Anatomical Context for Chronic Inflammatory Demyelinating Polyneuropathy

MalaCards organs/tissues related to Chronic Inflammatory Demyelinating Polyneuropathy:

42
T Cells, Bone, Skin, Spinal Cord, Endothelial, B Cells, Brain

Publications for Chronic Inflammatory Demyelinating Polyneuropathy

Articles related to Chronic Inflammatory Demyelinating Polyneuropathy:

(show top 50) (show all 638)
# Title Authors Year
1
Intravenous immunoglobulin G use in patients with chronic inflammatory demyelinating polyneuropathy: An uncommon cause of drug-induced discoid lupus erythematosus. ( 30734274 )
2019
2
Measuring disease activity and predicting response to intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy. ( 30805188 )
2019
3
Efficacy and Safety of Octagam® in Patients With Chronic Inflammatory Demyelinating Polyneuropathy. ( 30903535 )
2019
4
Electrodiagnostic data-driven clustering identifies a prognostically different subgroup of patients with chronic inflammatory demyelinating polyneuropathy. ( 30904899 )
2019
5
Simultaneous MR neurography and apparent T2 mapping in brachial plexus: Evaluation of patients with chronic inflammatory demyelinating polyradiculoneuropathy. ( 30266626 )
2019
6
Nerve echogenicity and intranerve CSA variability in high-resolution nerve ultrasound (HRUS) in chronic inflammatory demyelinating polyneuropathy (CIDP). ( 30554264 )
2019
7
Clinical and economic comparison of an individualised immunoglobulin protocol vs. standard dosing for chronic inflammatory demyelinating polyneuropathy. ( 30556098 )
2019
8
Cost of illness, cost of immunoglobulin therapy and their determinants in chronic inflammatory demyelinating polyneuropathy. ( 30620095 )
2019
9
Incidence and Prevalence of Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Systematic Review and Meta-Analysis. ( 30669140 )
2019
10
Restabilization treatment after IVIG withdrawal in chronic inflammatory demyelinating polyneuropathy. Results from the pre-randomization phase of the Polyneuropathy and Treatment with Hizentra® (PATH) study. ( 30672067 )
2019
11
Absence of pathogenic mutations in CD59 in chronic inflammatory demyelinating polyradiculoneuropathy. ( 30794663 )
2019
12
Polyneuropathies and chronic inflammatory demyelinating polyradiculoneuropathy in multiple sclerosis. ( 30870805 )
2019
13
Chronic inflammatory demyelinating polyneuropathy misdiagnosis: A clinical more than electrophysiogical problem? ( 29406592 )
2018
14
Onset of fulminant type 1 diabetes mellitus under immunotolerance status after long-term therapy for chronic inflammatory demyelinating polyneuropathy. ( 29905029 )
2018
15
Cerebrospinal Fluid Cytokine Expression Profile in Multiple Sclerosis and Chronic Inflammatory Demyelinating Polyneuropathy. ( 29182448 )
2018
16
Octagam<sup>Ar</sup> for chronic inflammatory demyelinating polyneuropathy: results from three observational studies. ( 29517417 )
2018
17
Nocebo in chronic inflammatory demyelinating polyneuropathy; a systematic review and meta-analysis of placebo-controlled clinical trials. ( 29627036 )
2018
18
A novel paraneoplastic syndrome with acquired lipodystrophy and chronic inflammatory demyelinating polyneuropathy in an adolescent male with craniopharyngioma. ( 29455190 )
2018
19
Vestibular impairment in chronic inflammatory demyelinating polyneuropathy. ( 29260355 )
2018
20
Elevated serum levels of endothelin-1 in patients with chronic inflammatory demyelinating polyneuropathy. ( 29137897 )
2018
21
Corticosteroids in chronic inflammatory demyelinating polyneuropathy : A retrospective, multicentre study, comparing efficacy and safety of daily prednisolone, pulsed dexamethasone, and pulsed intravenous methylprednisolone. ( 29968199 )
2018
22
Differences between acute-onset chronic inflammatory demyelinating polyneuropathy and acute inflammatory demyelinating polyneuropathy in adult patients. ( 29603827 )
2018
23
Subcutaneous IgG for chronic inflammatory demyelinating polyneuropathy. ( 29122522 )
2018
24
Neurofascin and Compact Myelin Antigen-Specific T Cell Response Pattern in Chronic Inflammatory Demyelinating Polyneuropathy Subtypes. ( 29615965 )
2018
25
Elevated leukocyte count in cerebrospinal fluid of patients with chronic inflammatory demyelinating polyneuropathy. ( 29341326 )
2018
26
Bilateral facial nerve palsies secondary to chronic inflammatory demyelinating polyneuropathy following adalimumab treatment. ( 29179036 )
2018
27
Drug-induced hypersensitivity syndrome followed by chronic inflammatory demyelinating polyneuropathy. ( 29671897 )
2018
28
High-resolution nerve ultrasound and magnetic resonance neurography as complementary neuroimaging tools for chronic inflammatory demyelinating polyneuropathy. ( 29552093 )
2018
29
Autoantibodies Against the Node of Ranvier in Seropositive Chronic Inflammatory Demyelinating Polyneuropathy: Diagnostic, Pathogenic, and Therapeutic Relevance. ( 29867996 )
2018
30
Does grip strength reflect isokinetic muscle strength in lower limbs in patients with chronic inflammatory demyelinating polyneuropathy? ( 29603302 )
2018
31
Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. ( 29122523 )
2018
32
Chronic inflammatory demyelinating polyneuropathy: evaluation of the vestibular system with cervical and ocular vestibular evoked myogenic potentials. ( 29700616 )
2018
33
Challenges in the diagnosis of chronic inflammatory demyelinating polyneuropathy. ( 29541543 )
2018
34
Outcome in chronic inflammatory demyelinating polyneuropathy from a Malaysian centre over sixteen years. ( 29398193 )
2018
35
Chronic inflammatory demyelinating polyneuropathy in adult T-cell leukemia-lymphoma patients following allogeneic stem cell transplantation. ( 30038356 )
2018
36
Reductions in muscle quality and quantity in chronic inflammatory demyelinating polyneuropathy patients assessed by magnetic resonance imaging. ( 29742800 )
2018
37
Employment status of patients with chronic inflammatory demyelinating polyradiculoneuropathy. ( 29999199 )
2018
38
Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial. ( 30001923 )
2018
39
Hereditary neuropathy with liability to pressure palsies mimicking chronic inflammatory demyelinating polyneuropathy. ( 30017102 )
2018
40
Conventional and unconventional therapies in typical and atypical chronic inflammatory demyelinating polyneuropathy with different clinical course of progression. ( 30027593 )
2018
41
Remission of chronic inflammatory demyelinating polyneuropathy after hepatitis C virus eradication with sofosbuvir and ledipasvir therapy. ( 30028899 )
2018
42
Clinical spectrum, treatment and outcome of children with suspected diagnosis of chronic inflammatory demyelinating polyradiculoneuropathy. ( 30072201 )
2018
43
Costs of illness in chronic inflammatory demyelinating polyneuropathy in Germany. ( 30073683 )
2018
44
Multifocal visual evoked potentials in chronic inflammatory demyelinating polyneuropathy. ( 30128319 )
2018
45
Nerve ultrasound can distinguish chronic inflammatory demyelinating polyneuropathy from demyelinating diabetic sensorimotor polyneuropathy. ( 30145079 )
2018
46
Lumbar plexus in patients with chronic inflammatory demyelinating polyradiculoneuropathy: evaluation with simultaneous T2 mapping and neurography method with SHINKEI. ( 30160180 )
2018
47
Rituximab in chronic inflammatory demyelinating polyradiculoneuropathy with associated diseases. ( 30203907 )
2018
48
Assessing the benefit of treatment in chronic inflammatory demyelinating polyneuropathy: the challenges of clinical practice. ( 30223714 )
2018
49
Association of neurofascin IgG4 and atypical chronic inflammatory demyelinating polyneuropathy: A systematic review and meta-analysis. ( 30240176 )
2018
50
Nerve Ultrasound, Electrophysiological, and Clinical Changes in Treatment-Naive Chronic Inflammatory Demyelinating Polyneuropathy: A Case Report. ( 30260816 )
2018

Variations for Chronic Inflammatory Demyelinating Polyneuropathy

Expression for Chronic Inflammatory Demyelinating Polyneuropathy

Search GEO for disease gene expression data for Chronic Inflammatory Demyelinating Polyneuropathy.

Pathways for Chronic Inflammatory Demyelinating Polyneuropathy

Pathways related to Chronic Inflammatory Demyelinating Polyneuropathy according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.11 CNTN2 NFASC
2
Show member pathways
10.72 CNTN2 NFASC

GO Terms for Chronic Inflammatory Demyelinating Polyneuropathy

Cellular components related to Chronic Inflammatory Demyelinating Polyneuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 myelin sheath GO:0043209 8.96 CNTN2 NFASC
2 node of Ranvier GO:0033268 8.62 CNTN2 NFASC

Biological processes related to Chronic Inflammatory Demyelinating Polyneuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neutrophil degranulation GO:0043312 9.33 HP NFASC TTR
2 defense response GO:0006952 9.32 FCGR2B HP
3 phagocytosis, engulfment GO:0006911 9.26 AIF1 FCGR2B
4 cerebellum development GO:0021549 8.96 AIF1 FCGR2B
5 protein localization to juxtaparanode region of axon GO:0071205 8.62 CNTN2 NFASC

Sources for Chronic Inflammatory Demyelinating Polyneuropathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....